Actively Recruiting
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
Led by University of California, San Francisco · Updated on 2026-05-01
50
Participants Needed
1
Research Sites
991 weeks
Total Duration
On this page
Sponsors
U
University of California, San Francisco
Lead Sponsor
N
National Institutes of Health (NIH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
HIV medicines have led to dramatic improvements in health. However, there remains a concern for potential drug toxicities, cost of drugs, and need for life-long treatment. In addition, research has found that health is not completely restored in HIV-infected patients, even if they have been taking effective HIV medicines for a long time. This may be due to direct drug-toxicity, continued replication of the virus, and/or inflammation of the body in response to the virus. Therefore, a more complete understanding of how HIV stays in the body is necessary. Recent research has shown that one of the places that HIV can stay in the body is in lymphatic tissues such as lymph nodes (even in patients who have been taking HIV medicines for a long time). In addition, the amount of damage to the lymphatic tissues can predict how the immune system (CD4+ T cell count) will respond to therapy. The investigators therefore propose a study in which lymph nodes from the groin area will be removed, with the goals of: 1) seeing how much HIV is in lymph nodes and 2) seeing how much damage has happened to the lymph node architecture.
CONDITIONS
Official Title
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to give informed consent
- No contraindication to surgical procedures
- Palpable inguinal adenopathy at study entry
- For HIV positive subjects, must meet one of the following: on stable highly active antiretroviral therapy (HAART) with recent undetectable viral load (< 50 copies/mL) ("HAART suppressed"), untreated with undetectable viral load (< 50 copies/mL) ("elite" controllers), or untreated with detectable viral load (> 1000 copies/mL) ("non-controllers")
You will not qualify if you...
- Known anemia (HIV+ males Hct <34; females Hct <32) or contraindication to donating blood
- Blood coagulation disorder including bleeding tendency or past problems with blood clots
- Platelet count less than 50,000/mm3
- Partial thromboplastin time (PTT) greater than 2 times the upper limit of normal
- International normalized ratio (INR) greater than 1.5
- Pregnant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
San Francisco General Hospital
San Francisco, California, United States, 94110
Actively Recruiting
Research Team
R
Rebecca Hoh, RD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here